ADPT vs. TRML, CRBU, AURA, ITOS, REPL, TNYA, LXEO, TCRX, SLDB, and VYGR
Should you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Tourmaline Bio (TRML), Caribou Biosciences (CRBU), Aura Biosciences (AURA), iTeos Therapeutics (ITOS), Replimune Group (REPL), Tenaya Therapeutics (TNYA), Lexeo Therapeutics (LXEO), TScan Therapeutics (TCRX), Solid Biosciences (SLDB), and Voyager Therapeutics (VYGR). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, community ranking, earnings, media sentiment and risk.
Tourmaline Bio presently has a consensus target price of $61.80, indicating a potential upside of 301.04%. Adaptive Biotechnologies has a consensus target price of $6.80, indicating a potential upside of 168.77%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Tourmaline Bio is more favorable than Adaptive Biotechnologies.
Tourmaline Bio has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Tourmaline Bio has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Tourmaline Bio has a net margin of 0.00% compared to Tourmaline Bio's net margin of -132.29%. Adaptive Biotechnologies' return on equity of -30.86% beat Tourmaline Bio's return on equity.
In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 2 mentions for Adaptive Biotechnologies and 1 mentions for Tourmaline Bio. Adaptive Biotechnologies' average media sentiment score of 1.41 beat Tourmaline Bio's score of 0.08 indicating that Tourmaline Bio is being referred to more favorably in the media.
Adaptive Biotechnologies received 82 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 56.52% of users gave Adaptive Biotechnologies an outperform vote.
91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 16.5% of Tourmaline Bio shares are owned by company insiders. Comparatively, 5.2% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Tourmaline Bio beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.
Get Adaptive Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptive Biotechnologies Competitors List
Related Companies and Tools
